Back to Search Start Over

Polymer Coated Oncolytic Adenovirus to Selectively Target Hepatocellular Carcinoma Cells.

Authors :
Garofalo M
Bellato F
Magliocca S
Malfanti A
Kuryk L
Rinner B
Negro S
Salmaso S
Caliceti P
Mastrotto F
Source :
Pharmaceutics [Pharmaceutics] 2021 Jun 24; Vol. 13 (7). Date of Electronic Publication: 2021 Jun 24.
Publication Year :
2021

Abstract

Despite significant advances in chemotherapy, the overall prognosis of hepatocellular carcinoma (HCC) remains extremely poor. HCC targeting strategies were combined with the tumor cell cytotoxicity of oncolytic viruses (OVs) to develop a more efficient and selective therapeutic system. OVs were coated with a polygalactosyl- b -agmatyl diblock copolymer (Gal <subscript>32</subscript> - b -Agm <subscript>29</subscript> ), with high affinity for the asialoglycoprotein receptor (ASGPR) expressed on the liver cell surface, exploiting the electrostatic interaction of the positively charged agmatine block with the negatively charged adenoviral capsid surface. The polymer coating altered the viral particle diameter (from 192 to 287 nm) and zeta-potential (from -24.7 to 23.3 mV) while hiding the peculiar icosahedral symmetrical OV structure, as observed by TEM. Coated OVs showed high potential therapeutic value on the human hepatoma cell line HepG2 (cytotoxicity of 72.4% ± 4.96), expressing a high level of ASGPRs, while a lower effect was attained with ASPGR-negative A549 cell line (cytotoxicity of 54.4% ± 1.59). Conversely, naked OVs showed very similar effects in both tested cell lines. Gal <subscript>32</subscript> - b -Agm <subscript>29</subscript> OV coating enhanced the infectivity and immunogenic cell death program in HepG2 cells as compared to the naked OV. This strategy provides a rationale for future studies utilizing oncolytic viruses complexed with polymers toward effective treatment of hepatocellular carcinoma.

Details

Language :
English
ISSN :
1999-4923
Volume :
13
Issue :
7
Database :
MEDLINE
Journal :
Pharmaceutics
Publication Type :
Academic Journal
Accession number :
34202714
Full Text :
https://doi.org/10.3390/pharmaceutics13070949